Answers are grounded in this paper and cite their sources.
Descriptive review observes widespread use of putative hepatoprotective agents during tuberculosis treatment across Eastern Europe, highlighting variation from standard international guidelines.
Putative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.
No takes yet. Share an insight, caveat, or question.
Kirakosyan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: